Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2021 08:10 ET | Source: InveniAI LLC

InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis

Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
April 27, 2021 08:10 ET | Source: InveniAI LLC

InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration

Teams will work together by leveraging InveniAI's technology to identify, evaluate, and optimize novel targets for drug discoveryShionogi will synthesize and develop compounds for targets identified...
December 09, 2020 08:10 ET | Source: InveniAI

InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration

Expansion of existing collaboration will leverage InveniAI® technology to identify, evaluate, and optimize novel targets for Kyowa Kirin’s antibody technologyKyowa Kirin will select multiple programs...
September 09, 2020 08:10 ET | Source: InveniAI

InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways

Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...

keyboard_arrow_left Previous Page